ArticleJournal of immunology research2019
Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against Zika Virus: A Study in the Mexican Population.
Article in Journal of immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 29 citations in OpenAlex.
- Antiviral efficacy of Trappin-2/Elafin against Zika virus in the human keratinocyte HaCaT cell line.Archives of virology · 2026Article
- Challenges and Opportunities in the Development of Dengue Vaccines: A Comprehensive Review.Advanced biomedical research · 2026Review
- Review
- Review
- Dengue Virus Infection: Immune Response and Therapeutic Targets.The American journal of tropical medicine and hygiene · 2025Review
- Animal Models, Therapeutics, and Vaccine Approaches to Emerging and Re-Emerging Flaviviruses.Viruses · 2024Review
- A comprehensive insight on the challenges for COVID-19 vaccine: A lesson learnt from other viral vaccines.Heliyon · 2023Review
- Dengue virus infection - a review of pathogenesis, vaccines, diagnosis and therapy.Virus research · 2023Review
- Serological evidence of possible high levels of undetected transmission of Zika virus among Papua New Guinea military personnel, 2019.IJID regions · 2022Article
- Mucosal Vaccination: A Promising Alternative Against Flaviviruses.Frontiers in cellular and infection microbiology · 2022Review
- Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines.Frontiers in immunology · 2022Review
- Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection.BMC immunology · 2021Article
- Hide and Seek: The Interplay Between Zika Virus and the Host Immune Response.Frontiers in immunology · 2021Review
- Robust Plasma Cell Response to Skin-Inoculated Dengue Virus in Mice.Journal of immunology research · 2021Article
- Article
- The Ability of Zika virus Intravenous Immunoglobulin to Protect From or Enhance Zika Virus Disease.Frontiers in immunology · 2021Article
- Zika virus serological diagnosis: commercial tests and monoclonal antibodies as tools.The journal of venomous animals and toxins including tropical diseases · 2020Review
- Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study.The Lancet. Neurology · 2020Observational
- Protection against dengue virus requires a sustained balance of antibody and T cell responses.Current opinion in virology · 2020Review
- COVID-19 in India: Are Biological and Environmental Factors Helping to Stem the Incidence and Severity?Aging and disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zika virus (ZIKV), an emerging mosquito-borne flavivirus, has quickly spread in many regions around the world where dengue virus (DENV) is endemic. This represents a major health concern, given the high homology between these two viruses, which can result in cross-reactivity. The aim of this study was to determine the cross-reacting antibody response of the IgM and IgG classes against the recombinant envelope protein of ZIKV (rE-ZIKV) in sera from patients with acute-phase infection of different clinical forms of dengue, i.e., dengue fever (DF) and dengue hemorrhagic fever (DHF) (before the arrival of ZIKV in Mexico 2010), as well as acute-phase sera of ZIKV patients, together with the implications in neutralization and antibody-dependent enhancement. Differences in IgM responses were observed in a number of DF and DHF patients whose sera cross-reacted with the rE-ZIK antigen, with 42% recognition between acute-phase DHF and ZIKV but 27% recognition between DF and ZIKV. Regarding IgG antibodies, 71.5% from the DF group showed cross-reactivity to rE-ZIKV in contrast with 50% and only 25% of DHF and ZIKV serum samples, respectively, which specifically recognized the homologous antigen. The DHF group showed more enhancement of ZIKV infection of FCR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.